$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2017 Q2 Form 10-Q Financial Statement

#000162828017004992 Filed on May 05, 2017

Income Statement

Concept	2017 Q2	2017 Q1	2016 Q1
Revenue	$18.00K	$18.00K	$489.0K
YoY Change	-96.27%	-96.32%	-88.36%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$7.060M	$3.960M	$5.100M
YoY Change	92.9%	-22.35%	40.11%
% of Gross Profit
Research & Development	$14.28M	$15.75M	$16.76M
YoY Change	-20.71%	-6.04%	24.85%
% of Gross Profit
Depreciation & Amortization	$660.0K	$699.0K	$419.0K
YoY Change	29.41%	66.83%	6.35%
% of Gross Profit
Operating Expenses	$21.34M	$19.71M	$21.87M
YoY Change	-1.55%	-9.86%	28.09%
Operating Profit	-$21.32M	-$19.69M	-$21.38M
YoY Change	0.61%	-7.88%	66.09%
Interest Expense	$603.0K	$546.0K	$24.00K
YoY Change	570.0%	2175.0%	200.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$21.74M	-$20.03M	-$21.21M
YoY Change	3.02%	-5.6%	46.38%
Income Tax	-$128.0K	-$4.000K	-$5.000K
% Of Pretax Income
Net Earnings	-$21.61M	-$20.02M	-$21.21M
YoY Change	2.46%	-5.59%	46.39%
Net Earnings / Revenue	-120044.44%	-111227.78%	-4336.81%
Basic Earnings Per Share			-$0.40
Diluted Earnings Per Share	-$4.878M	-$4.529M	-$4.831M
COMMON SHARES
Basic Shares Outstanding	53.18M shares	52.93M shares	52.70M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q2	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$40.10M	$57.50M	$105.1M
YoY Change	-62.7%	-45.29%	-29.37%
Cash & Equivalents	$12.54M	$14.89M	$19.25M
Short-Term Investments	$27.50M	$42.60M	$85.80M
Other Short-Term Assets	$3.018M	$3.534M	$410.0K
YoY Change	478.16%	761.95%	-91.63%
Inventory
Prepaid Expenses	$6.149M	$6.212M	$9.272M
Receivables	$700.0K	$400.0K	$100.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$49.94M	$67.65M	$115.8M
YoY Change	-57.03%	-41.56%	-26.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.75M	$11.27M	$10.96M
YoY Change	-12.73%	2.87%	218.12%
Goodwill
YoY Change
Intangibles	$823.0K	$920.0K	$1.069M
YoY Change	-22.5%	-13.94%	-1.66%
Long-Term Investments
YoY Change
Other Assets	$340.0K	$335.0K	$354.0K
YoY Change	9.68%	-5.37%	-80.33%
Total Long-Term Assets	$11.92M	$12.53M	$12.38M
YoY Change	-12.98%	1.18%	95.53%
TOTAL ASSETS
Total Short-Term Assets	$49.94M	$67.65M	$115.8M
Total Long-Term Assets	$11.92M	$12.53M	$12.38M
Total Assets	$61.86M	$80.17M	$128.1M
YoY Change	-52.39%	-37.43%	-22.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.901M	$4.509M	$3.622M
YoY Change	39.87%	24.49%	35.3%
Accrued Expenses	$4.717M	$4.690M	$5.456M
YoY Change	-13.8%	-14.04%	2.59%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.12M	$10.58M	$11.01M
YoY Change	0.23%	-3.95%	-23.27%
LONG-TERM LIABILITIES
Long-Term Debt	$19.80M	$19.80M	$0.00
YoY Change	0.0%
Other Long-Term Liabilities	$283.0K	$214.0K	$7.850M
YoY Change	-96.7%	-97.27%	769.32%
Total Long-Term Liabilities	$283.0K	$214.0K	$7.850M
YoY Change	-96.7%	-97.27%	769.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.12M	$10.58M	$11.01M
Total Long-Term Liabilities	$283.0K	$214.0K	$7.850M
Total Liabilities	$41.87M	$41.45M	$20.91M
YoY Change	0.92%	98.22%	16.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$315.6M	-$294.0M	-$212.7M
YoY Change	34.97%	38.2%	41.57%
Common Stock	$335.7M	$332.8M	$320.0M
YoY Change	4.13%	3.99%	7.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$20.00M	$38.73M	$107.2M
YoY Change
Total Liabilities & Shareholders Equity	$61.86M	$80.17M	$128.1M
YoY Change	-52.39%	-37.43%	-22.27%

Cashflow Statement

Concept	2017 Q2	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$21.61M	-$20.02M	-$21.21M
YoY Change	2.46%	-5.59%	46.39%
Depreciation, Depletion And Amortization	$660.0K	$699.0K	$419.0K
YoY Change	29.41%	66.83%	6.35%
Cash From Operating Activities	-$17.33M	-$18.68M	-$8.930M
YoY Change	-0.12%	109.18%	-20.64%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$139.0K	$395.0K
YoY Change	-84.62%	-64.81%	67.37%
Acquisitions
YoY Change
Other Investing Activities	$14.96M	$18.50M	$12.09M
YoY Change	189.36%	53.02%	-269.09%
Cash From Investing Activities	$14.98M	$18.36M	$11.69M
YoY Change	182.64%	57.04%	-258.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$265.0K	$363.0K
YoY Change		-27.0%	41.25%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$268.0K	$528.0K
YoY Change	-100.0%	-49.24%	-42.3%
NET CHANGE
Cash From Operating Activities	-17.33M	-$18.68M	-$8.930M
Cash From Investing Activities	14.98M	$18.36M	$11.69M
Cash From Financing Activities	0.000	$268.0K	$528.0K
Net Change In Cash	-2.350M	-$52.00K	$3.289M
YoY Change	-130.21%	-101.58%	-118.55%
FREE CASH FLOW
Cash From Operating Activities	-$17.33M	-$18.68M	-$8.930M
Capital Expenditures	$20.00K	$139.0K	$395.0K
Free Cash Flow	-$17.35M	-$18.82M	-$9.325M
YoY Change	-0.74%	101.81%	-18.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5840000	USD
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4509000	USD
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53182330	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
CY2017Q1	dei	Trading Symbol TradingSymbol	RGLS
CY2017Q1	rgls	Cashand Cash Equivalentsand Marketable Securities CashandCashEquivalentsandMarketableSecurities	57500000	USD
CY2017Q1	rgls	Effective Income Tax Rate Reconciliation Sharebased Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount	7400000	USD
CY2016Q4	rgls	Prepaid Expenses Reserve PrepaidExpensesReserve	600000	USD
CY2017Q1	rgls	Prepaid Expenses Reserve PrepaidExpensesReserve	600000	USD
CY2016Q1	rgls	Restricted Cash Tenant Improvement Allowance RestrictedCashTenantImprovementAllowance	-338000	USD
CY2017Q1	rgls	Restricted Cash Tenant Improvement Allowance RestrictedCashTenantImprovementAllowance	0	USD
CY2017Q1	rgls	Short Term Investment Maturity Weighted Average ShortTermInvestmentMaturityWeightedAverage	P2Y
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1657000	USD
CY2017Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	439000	USD
CY2016Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-198000	USD
CY2017Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-107000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5577000	USD
CY2017Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4690000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-123000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-97000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	329496000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	332746000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3749000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2381000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2413720	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1824296	shares
CY2016Q4	us-gaap	Assets Assets	100661000	USD
CY2017Q1	us-gaap	Assets Assets	80174000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	87474000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	67649000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	61170000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	42575000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	12000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	78000	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	32000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	61236000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	42600000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	86000	USD
CY2017Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15960000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19249000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14941000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14889000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3289000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-52000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13603716	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52924805	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53182330	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52924805	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53182330	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2017Q1	us-gaap	Common Stock Value CommonStockValue	53000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21167000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19995000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8840000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8864000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	72000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1993000	USD
CY2017Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	1975000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	419000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	699000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2318000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1306000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5103000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3959000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21212000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20025000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4000	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-9959000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1218000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	906000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1331000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-596000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-818000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	87000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	13000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-489000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-18000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1181000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1012000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2368000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-627000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1593000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	660000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1015000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	920000	USD
CY2016Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	190000	USD
CY2017Q1	us-gaap	Interest And Other Income InterestAndOtherIncome	214000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	24000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	546000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	5000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	465000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	44586000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	41446000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	100661000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80174000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13807000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10577000	USD
CY2016Q4	us-gaap	Long Term Debt LongTermDebt	19802000	USD
CY2017Q1	us-gaap	Long Term Debt LongTermDebt	19816000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	528000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	268000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11691000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	18360000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8930000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18680000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-21207000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-20021000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	21867000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	19711000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-21378000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19693000	USD
CY2016Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4154000	USD
CY2017Q1	us-gaap	Other Assets Current OtherAssetsCurrent	3534000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	342000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	335000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	40000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	26000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	144000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	214000	USD
CY2016Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	0	USD
CY2017Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	135000	USD
CY2016Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	5470000	USD
CY2017Q1	us-gaap	Other Significant Noncash Transaction Value Of Consideration Received1 OtherSignificantNoncashTransactionValueOfConsiderationReceived1	0	USD
CY2016Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11000	USD
CY2017Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	395000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	139000	USD
CY2016Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	20475000	USD
CY2017Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	2265000	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5552000	USD
CY2017Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	6212000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	363000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	265000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.26
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3749000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2381000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	688000	shares
CY2016Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	32572000	USD
CY2017Q1	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	20780000	USD
CY2016Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	206000	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11830000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11270000	USD
CY2016Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	41000	USD
CY2017Q1	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16764000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15752000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1300000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-273351000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-293974000	USD
CY2016Q1	us-gaap	Revenues Revenues	489000	USD
CY2017Q1	us-gaap	Revenues Revenues	18000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1796000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8931000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10031000	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10030972	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.70
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.77
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.38
CY2017Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.30
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	61170000	USD
CY2017Q1	us-gaap	Short Term Investments ShortTermInvestments	42575000	USD
CY2017Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	8000	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	56075000	USD
CY2017Q1	us-gaap	Stockholders Equity StockholdersEquity	38728000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52710672	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52990383	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our condensed financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-004992-index-headers.html	Edgar Link	pending
0001628280-17-004992-index.html	Edgar Link	pending
0001628280-17-004992.txt	Edgar Link	pending
0001628280-17-004992-xbrl.zip	Edgar Link	pending
ex-101xjosephhaganannualsa.htm	Edgar Link	pending
ex-102xtimothywrightannual.htm	Edgar Link	pending
ex-103xpaulgrintannualsala.htm	Edgar Link	pending
ex-311x20170331.htm	Edgar Link	pending
ex-312x20170331.htm	Edgar Link	pending
ex-321x20170331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20170331.xml	Edgar Link	completed
rgls-20170331.xsd	Edgar Link	pending
rgls-20170331_cal.xml	Edgar Link	unprocessable
rgls-20170331_def.xml	Edgar Link	unprocessable
rgls-20170331_lab.xml	Edgar Link	unprocessable
rgls-20170331_pre.xml	Edgar Link	unprocessable
rgls20170331-10q.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2017 Q2 Form 10-Q Financial Statement

#000162828017004992 Filed on May 05, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2017 Q2 Form 10-Q Financial Statement

#000162828017004992 Filed on May 05, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls